322 related articles for article (PubMed ID: 1783775)
1. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
Gorelick KJ; Chmel H
Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
[TBL] [Abstract][Full Text] [Related]
2. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
3. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Calandra T; Baumgartner JD; Glauser MP
Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to endotoxin in the management of sepsis.
Fang KC
West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
[TBL] [Abstract][Full Text] [Related]
5. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
6. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
[TBL] [Abstract][Full Text] [Related]
7. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
[TBL] [Abstract][Full Text] [Related]
8. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
9. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides.
Parent JB; Gazzano-Santoro H; Wood DM; Lim E; Pruyne PT; Trown PW; Conlon PJ
Circ Shock; 1992 Sep; 38(1):63-73. PubMed ID: 1382882
[TBL] [Abstract][Full Text] [Related]
10. Role of monoclonal antibody therapy in the treatment of infectious disease.
Chmel H
Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S11-5. PubMed ID: 2275476
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
Fink MP
Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
[TBL] [Abstract][Full Text] [Related]
13. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of endotoxemia and septicemia.
Baumgartner JD; Glauser MP
Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
[TBL] [Abstract][Full Text] [Related]
15. Antiendotoxin therapies for septic shock.
Corriveau CC; Danner RL
Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gram-negative infections.
Greenberg RN; Wilson KM; Kunz AY; Wedel NI; Gorelick KJ
Prog Clin Biol Res; 1991; 367():179-86. PubMed ID: 1924426
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
Mehra IV; Gottlieb JE; Nash DB
Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
[TBL] [Abstract][Full Text] [Related]
18. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
Smith CR; Straube RC; Ziegler EJ
Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
[TBL] [Abstract][Full Text] [Related]
19. Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides.
Wood DM; Parent JB; Gazzano-Santoro H; Lim E; Pruyne PT; Watkins JM; Spoor ES; Reardan DT; Trown PW; Conlon PJ
Circ Shock; 1992 Sep; 38(1):55-62. PubMed ID: 1394865
[TBL] [Abstract][Full Text] [Related]
20. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
